We are focused on the rapid design and development of new medicines based on breakthroughs in cancer research.
Firm Analyst
Peter Lawson
BofA Securities
Tazeen Ahmad
H.C. Wainwright
Robert Burns
Roger Song
Morgan Stanley
Jeffrey Hung

Prelude Therapeutics is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Prelude Therapeutics's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Prelude Therapeutics or its management. Prelude Therapeutics does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.